Clinical evaluation of a new alkylating agent, Azetepa, in one hundred and twenty-five cases of malignant tumors

1967 ◽  
Vol 2 (2) ◽  
pp. 189-193 ◽  
Author(s):  
Daniel S. J. Choy ◽  
Jose Arandia ◽  
Isaac Rosenbaum
Keyword(s):  
Clinical Evaluation ◽  
Alkylating Agent ◽  
Malignant Tumors

scholarly journals Clinical Evaluation of Immunological Parameters in Patients with Malignant Tumors of Head and Neck

1989 ◽  
Vol 1989 (Supplement33) ◽  
pp. 127-135
Author(s):  
Junichi Yoda ◽  
Tadahito Saito ◽  
Takaaki Kawaguchi ◽  
Hiroki Arai ◽  
Toshihide Tabata
Keyword(s):  
Head And Neck ◽  
Clinical Evaluation ◽  
Malignant Tumors ◽  
Immunological Parameters

scholarly journals Approach to the Treatment of a Patient with an Aggressive Pituitary Tumor

2020 ◽  
Vol 105 (12) ◽  
pp. 3807-3820
Author(s):  
Andrew L Lin ◽  
Mark T A Donoghue ◽  
Sharon L Wardlaw ◽  
T Jonathan Yang ◽  
Lisa Bodei ◽  
...  
Keyword(s):  
Alkylating Agent ◽  
Malignant Tumors ◽  
Checkpoint Inhibitors ◽  
Objective Response ◽  
Unmet Need ◽  
Pituitary Tumors ◽  
Small Subset ◽  
Tumor Type ◽  
Time To Progression ◽  
Aggressive Tumors

Abstract A small subset of pituitary adenomas grows despite maximal treatment with standard therapies; namely, surgery and radiotherapy. These aggressive tumors demonstrate 2 patterns of growth: they may be locally aggressive or metastasize distantly, either hematogenously or through the spinal fluid. Further surgery and radiotherapy may be helpful for palliation of symptoms, but they are rarely definitive in the management of these malignant tumors. The only chemotherapy with established activity in the treatment of pituitary tumors is the alkylating agent temozolomide. At most, 50% of patients exhibit an objective response to temozolomide and the median time to progression is short; thus, there remains a significant unmet need for effective treatments within this patient population. Several targeted agents have reported activity in this tumor type—including small molecule inhibitors, checkpoint inhibitors, and other biologics—but remain investigational at this time.

Clinical evaluation of thermography in the diagnosis of malignant tumors in the oral and maxillo-facial region

1992 ◽  
Vol 8 (1) ◽  
pp. 11-17 ◽  
Author(s):  
Yasuhiro Hayase ◽  
Toru Wakasa ◽  
Masato Uemura ◽  
Kiyoyuki Adachi ◽  
Satoru Ochi ◽  
...  
Keyword(s):  
Clinical Evaluation ◽  
Malignant Tumors ◽  
Facial Region

Clinical evaluation of a new alkylating agent: Cytoxan (cyclophosphamide)

Cancer ◽  
1960 ◽  
Vol 13 (6) ◽  
pp. 1254-1260 ◽  
Author(s):  
Peter R. Coggins ◽  
Robert G. Ravdin ◽  
Sylvan H. Eisman
Keyword(s):  
Clinical Evaluation ◽  
Alkylating Agent

CLINICAL-EVALUATION OF SERUM BASIC FETOPROTEIN AS A MARKER IN UROGENITAL MALIGNANT-TUMORS

1995 ◽  
Author(s):  
A GOTOH ◽  
K HARADA ◽  
K GOHJI ◽  
S ARAKAWA ◽  
S KAMIDONO
Keyword(s):  
Clinical Evaluation ◽  
Malignant Tumors ◽  
Basic Fetoprotein

262 POSTER Pre-clinical evaluation of the novel alkylating agent RH1 against paediatric tumour cell lines

2006 ◽  
Vol 4 (12) ◽  
pp. 84
Author(s):  
D. Hussein ◽  
K. Brookes ◽  
T. Ward ◽  
E. Estlin ◽  
C. Dive ◽  
...  
Keyword(s):  
Cell Lines ◽  
Clinical Evaluation ◽  
Tumour Cell ◽  
Alkylating Agent ◽  
The Novel ◽  
Tumour Cell Lines

scholarly journals Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors

2005 ◽  
Vol 16 (8) ◽  
pp. 1391-1397 ◽  
Author(s):  
S.N. Holden ◽  
S.G. Eckhardt ◽  
R. Basser ◽  
R. de Boer ◽  
D. Rischin ◽  
...  
Keyword(s):  
Clinical Evaluation ◽  
Egf Receptor ◽  
Malignant Tumors ◽  
Receptor Signaling ◽  
Active Inhibitor ◽  
Orally Active ◽  
Solid Malignant Tumors

scholarly journals Pre-clinical evaluation of [111In]-benzyl-DOTA-ZHER2:342, a potential agent for imaging of HER2 expression in malignant tumors

2007 ◽  
Author(s):  
Anna Orlova ◽  
Thuy Tran ◽  
Charles Widström ◽  
Torun Engfeldt ◽  
Amelie Eriksson Karlström ◽  
...  
Keyword(s):  
Clinical Evaluation ◽  
Malignant Tumors ◽  
Her2 Expression

P.169 Clinical evaluation of FDG-PET for oral malignant tumors

2008 ◽  
Vol 36 ◽  
pp. S210
Author(s):  
R. Matsubara ◽  
S. Kawano ◽  
K. Oobu ◽  
T. Chikui ◽  
Y. Nakao ◽  
...  
Keyword(s):  
Clinical Evaluation ◽  
Fdg Pet ◽  
Malignant Tumors
Sign in / Sign up

Export Citation Format

Share Document